South Korea’s pharma industry has a valuable pool of promising drugs, but China still leads the way in out-licensing deals.

GSK and CureVac will together receive $740 million, as well as royalties on sales of COVID-19 vaccines in the US ...

PIVOT-PO Phase 3 trial evaluating tebipenem Hbr in complicated urinary tract infection (cUTI) patients stopped early for ...

London: GSK plc has announced that a supplemental New Drug Application for gepotidacin has been accepted by the US Food and ...

After a slow 2024, the biotech shell company Concentra Biosciences is back, offering to buy four biotechs in the past month ...

GSK plc announced the acquisition of ordinary shares by several key executives under the Company’s Share Reward Plan. This transaction, conducted on the London Stock Exchange, involved the purchase of ...

Theravance Biopharma's Q2 2025 earnings show robust growth with YUPELRI sales up 22%, a $225M TRELEGY royalty sale, and progress in the pivotal CYPRESS trial.

Spero Therapeutics ( ($SPRO) ) has provided an announcement. On August 12, 2025, Spero Therapeutics announced its second quarter 2025 financial ...

Theravance Biopharma, Inc. ( NASDAQ: TBPH) Q2 2025 Earnings Conference Call August 12, 2025 5:00 PM ET Aine Miller - Senior VP of Development & Head of Ireland Office Aziz Sawaf - Senior VP & CFO ...

The 40 Under 40, Rami Fakhouri of Goldman Ismail is honored for his work in products liability.

South Korea is fast becoming a focal point for global biopharmaceutical licensing, with deal values reaching $7.86 billion ...

A number of stocks jumped in the afternoon session after positive inflation data fueled hopes for an interest rate cut by the Federal Reserve. The latest Consumer Price Index (CPI) report showed ...